PHARMACIES VISSOUL
ActiveSummary
The computed 12-month bankruptcy probability of PHARMACIES VISSOUL is 2.3% (moderate). The 2025 annual accounts show equity of €126,370 and a net result of -€78,268. Equity has been growing by about 22% per year since 2018. Its solvency ranks better than 25% of 12,757 sector peers (NACE 47, financial year 2025). The company has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals.
Overview
Official details
Source: KBO- Status
- Active since 20-09-2016 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2022
- Establishment units
- 2.257.468.924 4890 Thimister-Clermont, since 01-01-2017
- 2.257.469.023 4890 Thimister-Clermont, since 01-01-2017
- Financial year end
- 31 December
- Peppol
- Reachable since 24-11-2025
Board and ownership
- Cécile Joëlle ClaudeManaging director
- VISSOUL Marie Joséphine ThérèseManaging director
- VISSOUL CécileDirector
Financial position
- Bankruptcy probabilitywithin 12 months
- 2.3%
- Gross margin
- €543,531
- ▼ 1.3%
- Turnover
- ≈ €2.0m
- estimated
- Loss
- €78,268
- ▲ 364%
- Equity
- €126,370
- ▼ 38.2%
- Total assets
- €867,168
- ▼ 8.2%
- Employees on 31-12-2025
- 7
- ▲ 16.7%
- 2025 accounts filed 27 days after the deadline
Score breakdownraises riskLoss of €78,268, the second in a row (financial year 2025)Equity €126,370 (14.6% of total assets)Sector: Retail trade (NACE 47)lowers riskFigures for financial year 2025 (filed on 27-08-2026)Show the evidence
Checked score
About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 31% of them on solvency, 20% on liquidity, 21% on profitability and 13% on growth.
The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 19 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
Recent changes
- · Gazette deed Reappointments: VISSOUL Marie Joséphine Thérèse (director) and Cécile Joëlle Claude (director)Appointments: VISSOUL Marie Joséphine Thérèse (managing director) and Cécile Joëlle Claude (managing director)
- · Gazette deed Incorporation
Comparable companies
These companies have the same main activity as PHARMACIES VISSOUL: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €736,000 and €1.1m, founded between 2013 and 2018.
| Company | Total assets | Gross margin |
|---|---|---|
| PHARMACIES VISSOUL Thimister-Clermont | €0.9m | €0.5m |
| Rutgeerts – Grauwels Management Lanaken | €0.9m | €0.5m |
| PHARMACIE BERTRAND BRAIVES Braives | €1.1m | €0.5m |
| PHARMACIE CATHEDRALE Liège | €1.0m | €0.4m |
| PHARMA DEGEE Andenne | €1.0m | €0.5m |
| PHARMACIE DELVENNE Floreffe | €0.7m | €0.6m |
| A.K. PHARMA Sint-Agatha-Berchem | €0.9m | €0.4m |
Key facts about PHARMACIES VISSOUL
- What is the company number of PHARMACIES VISSOUL?
- The company number of PHARMACIES VISSOUL is 0662.738.147. The VAT number is the same number with BE in front: BE 0662.738.147.
- Where is PHARMACIES VISSOUL based?
- The registered office is at Centre 32, 4890 Thimister-Clermont.Company details
- What does PHARMACIES VISSOUL do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMACIES VISSOUL?
- The legal form of PHARMACIES VISSOUL is Private limited company (BV).
- When was PHARMACIES VISSOUL founded?
- PHARMACIES VISSOUL was founded on 20-09-2016.
- Is PHARMACIES VISSOUL still active?
- Yes, PHARMACIES VISSOUL is an active enterprise in the KBO register.
- How many employees does PHARMACIES VISSOUL have?
- PHARMACIES VISSOUL had an average of 5.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does PHARMACIES VISSOUL fall under?
- In its 2022 annual accounts, PHARMACIES VISSOUL states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of PHARMACIES VISSOUL?
- The turnover in financial year 2025 is ≈ €2.0m. This figure is estimated from the gross margin of €543,531 and 47 comparable companies (NACE 477). It probably lies between €1.5m and €3.2m.
- Is PHARMACIES VISSOUL profitable?
- In financial year 2025, PHARMACIES VISSOUL made a loss of €78,268.
- Where can I find the annual accounts of PHARMACIES VISSOUL?
- PHARMACIES VISSOUL filed 9 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMACIES VISSOUL due?
- PHARMACIES VISSOUL must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.